Sensitivity to MPTP is not increased in Parkinson's disease‐associated mutant α‐synuclein transgenic mice: RAPID COMMUNICATION

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,777

A Drosophila model of Parkinson's disease

Feany, M. Β., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,156

Dopaminergic Loss and Inclusion Body Formation in α-Synuclein Mice: Implications for Neurodegenerative Disorders

Masliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,779

Neuropathology of Parkinson's Disease

Forno, L. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,556

Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias

West, M. J. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01362-9 · Cited by 820

Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease

Hartmann, A., Hunot, S., Michel, P. P., Muriel, M., Vyas, S., Faucheux, B. A., Prigent, A., Turmel, H., Srinivasan, A. N., Ruberg, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040556597 · Cited by 717

Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain

Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van der Putten, H., Probst, A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06365.2000 · Cited by 642

Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Przedborski, S., Jackson-Lewis, V. R., Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624

Neuropathology in Mice Expressing Human α-Synuclein

van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06021.2000 · Cited by 563

Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro

Giasson, B. I., Uryu, K., Trojanowski, J. Q., & Lee, V. M. ‐. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7619 · Cited by 510

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

Lotharius, J., & Brundin, P. (2002) · Nature reviews. Neuroscience · doi:10.1038/nrn983 · Cited by 1,319

Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System

Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 649

Mitochondrial dysfunction in Parkinson's disease

Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688

Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences

Exner, N., Lutz, A. K., Haass, C., & Winklhofer, K. F. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.170 · Cited by 677

Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death

Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D., & Greene, L. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09549.2001 · Cited by 584

Parkin Protects against the Toxicity Associated with Mutant α-Synuclein

Petrucelli, L., O’Farrell, C., Lockhart, P. J., Baptista, M. J., Kehoe, K. J., Vink, L., Choi, P., Wolozin, B. L., Farrer, M. J., Hardy, J., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)01125-x · Cited by 561

Parkinson’s disease: animal models and dopaminergic cell vulnerability

Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 515

Synuclein activates microglia in a model of Parkinson's disease

Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474

Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease

Kirik, D., Annett, L. E., Bürger, C., Muzyczka, N., Mandel, R. J., & Björklund, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536383100 · Cited by 416

Misfolded proteinase K–resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies

Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W. P. J. M., Müller, V., Odoy, S., Fujiwara, H., Hasegawa, M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15777 · Cited by 363

The role of α-synuclein in Parkinson's disease: insights from animal models

Lad, E. M., Dass, B., Collier, T. J., Kordower, J. H., & Steece‐Collier, K. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1199 · Cited by 357

Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line

Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., & Brundin, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205518200 · Cited by 368

Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders

Tofaris, G. K., Garcia-Reitboeck, P., Humby, T., Lambourne, S. L., O’Connell, M. T., Ghetti, B. F., Gossage, H., Emson, P. C., Wilkinson, L. S., Goedert, M., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4965-05.2006 · Cited by 335

Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease

Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 313

Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice

Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285

Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease

Lotharius, J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2395 · Cited by 273

Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease

Dev, K. K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 267

α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration

Manning-Bog, A., McCormack, A. L., Purisai, M. G., Bolin, L. M., & Monte, D. A. D. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03095.2003 · Cited by 242

Dopaminergic Cell Loss Induced by Human A30P α -Synuclein Gene Transfer to the Rat Substantia Nigra

Klein, R. L., King, M. A., Hamby, M. E., & Meyer, E. M. (2002) · Human Gene Therapy · doi:10.1089/10430340252837206 · Cited by 212

Reverse engineering Lewy bodies: how far have we come and how far can we go?

Fares, M. B., Jagannath, S., & Lashuel, H. A. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-00416-6 · Cited by 205

The role of α-synuclein in neurodegenerative diseases

Bennett, M. C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.010 · Cited by 198

Neurotoxic in vivo models of Parkinson’s disease

Cannon, J. R., & Greenamyre, J. T. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84002-6 · Cited by 198

Gene–environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models

Cannon, J. R., & Greenamyre, J. T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.025 · Cited by 194

MPTP: a review of its mechanisms of neurotoxicity

Przedborski, S., & Vila, M. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00019-6 · Cited by 191

Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect

Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., & Chesselet, M. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.008 · Cited by 185

Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice

Gómez‐Isla, T., Irizarry, M. C., Mariash, A., Cheung, B. S., Soto, O., Schrump, S. E., Sondel, J., Kotilinek, L., Day, J., Schwarzschild, M. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00091-x · Cited by 181

Genes, proteins, and neurotoxins involved in Parkinson’s disease

Halbach, O. V. B. U., Schober, A., & KRIEGLSTEIN, K. G. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.002 · Cited by 180

Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice

Thiruchelvam, M. J., Powers, J. M., Cory‐Slechta, D. A., & Richfield, E. K. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03139.x · Cited by 174

Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson’s Disease: Involvement of α-Synuclein

Monti, B., Gatta, V., Piretti, F., Raffaelli, S. S., Virgili, M., & Contestabile, A. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9090-5 · Cited by 174

α-Synuclein Negatively Regulates Protein Kinase Cδ Expression to Suppress Apoptosis in Dopaminergic Neurons by Reducing p300 Histone Acetyltransferase Activity

Jin, H., Kanthasamy, A., Ghosh, A., Yang, Y., Anantharam, V., & Kanthasamy, A. G. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5634-10.2011 · Cited by 164

Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice

Robertson, D. C., Schmidt, O., Ninkina, N. N., Jones, P. A., Sharkey, J., & Buchman, V. L. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02378.x · Cited by 154

Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

Schlüter, O. M., Fornai, F., Alessandri, M., TAKAMORI, S., Geppert, M., Jahn, R., & Südhof, T. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00036-8 · Cited by 146

Genetics of parkinsonism

Gwinn, K. A. (2002) · Movement Disorders · doi:10.1002/mds.10173 · Cited by 139

MPTP

Speciale, S. G. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00222-2 · Cited by 133

Mutual exacerbation of peroxisome proliferator‐activated receptor γ coactivator 1α deregulation and α‐synuclein oligomerization

Eschbach, J., von Einem, B., Müller, K., Bayer, H., Scheffold, A., Morrison, B. E., Rudolph, K. L., Thal, D. R., Witting, A., Weydt, P., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24294 · Cited by 126

α-Synucleinopathy models and human neuropathology: similarities and differences

Kahle, P. J. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0302-x · Cited by 132

The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I

Litvan, I., Halliday, G. M., Hallett, M., Goetz, C. G., Rocca, W. A., Duyckaerts, C. J., Ben‐Shlomo, Y., Dickson, D. W., Lang, A. E., Chesselet, M., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3180415e42 · Cited by 122

Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α‐Synuclein

Lauwers, E., Debyser, Z., Dorpe, J. V., Strooper, B. D., Nuttin, B., & Baekelandt, V. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00035.x · Cited by 123

Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?

Maguire‐Zeiss, K. A., Short, D. W., & Federoff, H. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.014 · Cited by 115

Transgenic Models of α‐Synuclein Pathology

Hashimoto, M., Rockenstein, E. M., & Masliah, E. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07475.x · Cited by 108

Neurobiology of α-Synuclein

Vekrellis, K., Rideout, H. J., & Stefanis, L. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:1:001 · Cited by 108

The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration

Mor, D. E., Daniels, M. J., & Ischiropoulos, H. (2019) · Movement Disorders · doi:10.1002/mds.27607 · Cited by 107

Increased sensitivity to MPTP in human α-synuclein A30P transgenic mice

Nieto, M., Gil-Bea, F. J., Dalfó, E., Cuadrado‐Tejedor, M., Cabodevilla, F., Sánchez, B., Catena, S., Sesma, T., Ribé, E. M., Ferrer, I., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.010 · Cited by 100

Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human α-synuclein

Yavich, L., Oksman, M., Tanila, H., Kerokoski, P., Hiltunen, M. O., van Groen, T., Puoliväli, J. T., Männistö, P. T., Garcia-Horsman, A., MacDonald, E., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.010 · Cited by 103

Etiology of Parkinson's disease: Genetics and environment revisited

Steece‐Collier, K., Lad, E. M., & Kordower, J. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242594999 · Cited by 99

Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease

Trancikova, A. K., Tsika, E., & Moore, D. J. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4200 · Cited by 94

Using human neural stem cells to model neurological disease

Jakel, R. J., Schneider, B. L., & Svendsen, C. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1268 · Cited by 92

Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases

Schildknecht, S. (2013) · ALTEX · doi:10.14573/altex.2013.4.427 · Cited by 88

Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background

Cabin, D. E., Gispert-Sánchez, S., Murphy, D., Auburger, G. W. J., Myers, R. R., & Nussbaum, R. L. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.026 · Cited by 85

Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases

Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01020.x · Cited by 86

Oxidative Stress in Genetic Mouse Models of Parkinson’s Disease

Varçin, M., Bentea, E., Michotte, Y. M., & Sarre, S. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/624925 · Cited by 86

In vivo models of alpha-synuclein transmission and propagation

Recasens, A., Ulusoy, A., Kahle, P. J., Monte, D. A. D., & Dehay, B. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2730-9 · Cited by 77

Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia

Kawahata, I., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113779 · Cited by 71

Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling

Horowitz, M. P., & Greenamyre, J. T. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.138 · Cited by 72

Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation

Thomas, B., Mandir, A. S., West, N. C., Liu, Y., Andrabi, S. A., Stirling, W. L. H., Dawson, V. L., Dawson, T. M., & Lee, M. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016706 · Cited by 73

Expression of mutant ??-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro

Lehmensiek, V., Tan, E.-M., Schwarz, J., & Storch, A. (2002) · Neuroreport · doi:10.1097/00001756-200207190-00013 · Cited by 59

Convergent Pathobiologic Model of Parkinson's Disease

Maguire‐Zeiss, K. A., & Federoff, H. J. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07473.x · Cited by 58

Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse

Taylor, T. N., Potgieter, D., Anwar, S., Senior, S. L., Janezic, S., Threlfell, S., Ryan, B. J., Parkkinen, L., Deltheil, T., Cioroch, M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.005 · Cited by 57

Model fusion: The next phase in developing animal models for parkinson’s disease

Manning-Bog, A., & Langston, J. W. (2007) · Neurotoxicity Research · doi:10.1007/bf03033569 · Cited by 56

Alpha Synuclein in Parkinson’s Disease

Kragh, C. L., Romero‐Ramos, M., Halliday, G. M., & Jensen, P. H. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_14 · Cited by 48

Overexpression of Parkinson's disease‐associated α‐SynucleinA53T by recombinant adeno‐associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP

Dong, Z., Ferger, B., Feldon, J., & Büeler, H. (2002) · Journal of Neurobiology · doi:10.1002/neu.10094 · Cited by 47

DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson's disease

Hegde, M. L. (2009) · Frontiers in bioscience · doi:10.2741/3628 · Cited by 46

Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse

Song, L.-K., Ma, K., Yuan, Y., Mu, Z., Song, X., Niu, F., Han, N., & Chen, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131281 · Cited by 45

Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants

Wersinger, C., & Sidhu, A. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00212-x · Cited by 45

The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II

Litvan, I., Chesselet, M., Gasser, T., Monte, D. A. D., Parker, D., Hagg, T., Hardy, J., Jenner, P. G., Myers, R. H., Price, D. D., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318053716a · Cited by 45

Viral Vector Mediated Overexpression of Human α-Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease

Maingay, M., Romero‐Ramos, M., & Kirik, D. (2005) · CNS Spectrums · doi:10.1017/s1092852900010075 · Cited by 45

Altered short-term hippocampal synaptic plasticity in mutant α-synuclein transgenic mice

Steidl, J. V., Gómez‐Isla, T., Mariash, A., Ashe, K. H., & Boland, L. M. (2003) · Neuroreport · doi:10.1097/00001756-200302100-00012 · Cited by 44

Genetic factors involved in the pathogenesis of Parkinson's disease

Lee, F. J. S., & Liu, F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.02.001 · Cited by 43

α-Synuclein nonhuman primate models of Parkinson’s disease

Marmion, D. J., & Kordower, J. H. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1720-0 · Cited by 44

Influence of Different Promoters on the Expression Pattern of Mutated Human α-Synuclein in Transgenic Mice

Maskri, L., Zhu, X., Fritzen, S., Kühn, K., Ullmer, C., Engels, P., Andriske, M., Stichel, C. C., & Lübbert, H. (2004) · Neurodegenerative Diseases · doi:10.1159/000085064 · Cited by 41

Increased Dopaminergic Neuron Sensitivity to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Transgenic Mice Expressing Mutant A53T α-Synuclein

Yu, W. H., Matsuoka, Y., Sziráki, I., Hashim, A., LaFrancois, J. J., Sershen, H. W., & Duff, K. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9533-4 · Cited by 41

Early and late molecular events in neurodegeneration and neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron

Youdim, M. B. H., Grünblatt, E., Levites, Y., Maor, G., & Mandel, S. A. (2002) · Neurotoxicity Research · doi:10.1080/1029842021000045507 · Cited by 39

Transgenic animal models of neurodegeneration based on human genetic studies

Harvey, B. K., Richie, C. T., Hoffer, B. J., & Airavaara, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0476-6 · Cited by 38

Synucleins and their relationship to Parkinson’s disease

Halbach, O. V. B. U. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0921-7 · Cited by 37

α-Synuclein and nonhuman primate models of Parkinson's disease

Vermilyea, S., & Emborg, M. E. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.07.025 · Cited by 41

Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurones: Effects in wild type and human A30P mutant α-synuclein mice

Keane, P. C., Hanson, P. S., Patterson, L., Blain, P. G., Hepplewhite, P. D., Khundakar, A. A., Judge, S. J., Kahle, P. J., LeBeau, F. E. N., & Morris, C. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134437 · Cited by 38

Neurotoxin-Induced Rodent Models of Parkinson’s Disease: Benefits and Drawbacks

El‐Gamal, M., Salama, M., Collins‐Praino, L. E., Baetu, I., Fathalla, A. M., Soliman, A. M., Mohamed, W. M. Y., & Moustafa, A. A. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00356-8 · Cited by 40

Emerging evidence for the neuroprotective role of α-synuclein

Lee, H., Zhu, X., Takeda, A., Perry, G. L., & Smith, M. A. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.04.024 · Cited by 37

Alpha-synuclein: between synaptic function and dysfunction.

Rosa, G. D., Puzzo, D., Sant'Angelo, A., Trinchese, F., & Arancio, O. (2003) · PubMed · doi:10.14670/hh-18.1257 · Cited by 31

Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice

Szegő, É. M., Gerhardt, E., Outeiro, T. F., & Kermer, P. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.06.048 · Cited by 29

Modulation of α-synuclein expression in transgenic animals for modelling synucleinopathies — is the juice worth the squeeze?

Buchman, V. L., & Ninkina, N. N. (2008) · Neurotoxicity Research · doi:10.1007/bf03033857 · Cited by 29

Genome-Wide Microarray Analysis of the Differential Neuroprotective Effects of Antioxidants in Neuroblastoma Cells Overexpressing the Familial Parkinson’s Disease α-Synuclein A53T Mutation

Ma, L., Cao, T. T., Kandpal, G., Warren, L., Hess, J. F., Seabrook, G. R., & Ray, W. J. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0038-1 · Cited by 27

Chromosomal Loci Influencing the Susceptibility to the Parkinsonian Neurotoxin 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine

Sedelis, M., Hofele, K., Schwarting, R. K. W., Huston, J. P., & Belknap, J. K. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-23-08247.2003 · Cited by 27

Anti-apoptotic gene therapy in Parkinson’s disease

Schulz, J. B. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_70 · Cited by 26

A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice

Szegő, É. M., Gerhardt, E., Kermer, P., & Schulz, J. B. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.017 · Cited by 24

MPTP-induced vulnerability of dopamine neurons in A53T α-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation

Lee, S., Oh, S. T., Jeong, H. J., Pak, S. C., Park, H., Kim, J., Cho, H., & Jeon, S. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.6.625 · Cited by 24

Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain‐derived neurotrophic factor

Komnig, D., Dagli, T. C., Habib, P., Zeyen, T., Schulz, J. B., & Falkenburger, B. H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14575 · Cited by 24

Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?

Lee, H., Petersen, R. B., Zhu, X., Honda, K., Aliev, G., Smith, M. A., & Perry, G. L. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00491.x · Cited by 24

Environmental Toxins and α-Synuclein in Parkinson's Disease

Liu, Y., & Yang, H. (2005) · Molecular Neurobiology · doi:10.1385/mn:31:1-3:273 · Cited by 23

Identification of Allele-Specific RNAi Effectors Targeting Genetic Forms of Parkinson's Disease

Sibley, C. R., & Wood, M. J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026194 · Cited by 23

Lewy Body Disorders

Jellinger, K. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-30377-2_15 · Cited by 22

Impact of fatty acid-binding proteins and dopamine receptors on α-synucleinopathy

Kawahata, K., & Fukunaga, K. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.12.003 · Cited by 20

Literature-Related Discovery (LRD)

Kostoff, R. N., Block, J. A., Solka, J. L., Briggs, M. B., Rushenberg, R. L., Stump, J. A., Johnson, D., Lyons, T. J., & Wyatt, J. R. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada473438 · Cited by 19

Visualization of early oligomeric α‐synuclein pathology and its impact on the dopaminergic system in the (Thy‐1)‐h[A30P]α‐syn transgenic mouse model

Behere, A., Thörnqvist, P., Winberg, S., Ingelsson, M., Bergström, J. J. E., & Ekmark‐Lewén, S. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24927 · Cited by 18

Engineered modeling and the secrets of Parkinson's disease

Vila, M., Wu, D. C., & Przedborski, S. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01984-6 · Cited by 18

Mechanisms and models of α-synuclein-related neurodegeneration

Springer, W., & Kahle, P. J. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0025-8 · Cited by 16

Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains

Piltonen, M., Savolainen, M. H., Patrikainen, S., Baekelandt, V., Myöhänen, T. T., & Männistö, P. T. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.045 · Cited by 15

A β-Wrapin Targeting the N-Terminus of α-Synuclein Monomers Reduces Fibril-Induced Aggregation in Neurons

Szegő, É. M., Szegő, É. M., Boß, F., Komnig, D., Gärtner, C., Höfs, L., Shaykhalishahi, H., Wördehoff, M., Saridaki, T., Schulz, J. B., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.696440 · Cited by 15

Increased sensitivity to MPTP in human α-synuclein A30P transgenic mice

Nieto, M., Gil-Bea, F. J., Dalfó, E., Cuadrado‐Tejedor, M., Cabodevilla, F., Sánchez, B., Catena, S., Sesma, T., Ribé, E. M., Ferrer, I., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.010 · Cited by 100

Increased Dopaminergic Neuron Sensitivity to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Transgenic Mice Expressing Mutant A53T α-Synuclein

Yu, W. H., Matsuoka, Y., Sziráki, I., Hashim, A., LaFrancois, J. J., Sershen, H. W., & Duff, K. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9533-4 · Cited by 41

Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

Schlüter, O. M., Fornai, F., Alessandri, M., TAKAMORI, S., Geppert, M., Jahn, R., & Südhof, T. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00036-8 · Cited by 146

Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP

Dauer, W. T., Kholodilov, N. G., Vila, M., Trillat, A., Goodchild, R. E., Larsen, K. E., Staal, R. G. W., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 595

Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice

Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285